Kepivance® (palifermin) – Label update
July 1, 2016 – The FDA approved a safety update for Kepivance (palifermin) pertaining to the risk of exacerbated mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support.
Download PDF
